What they say:
A recent study from the Molecular Medicine Laboratory, International Centre for Genetic Engineering and Biotechnology (ICGEB), a United Nations organisation in Trieste, Trieste, Italy, School of Cardiovascular Medicine & Sciences, King’s College London British Heart Foundation Centre, London, UK, Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy, Institute of Life Sciences, Scuola Superiore Sant’Anna, Pisa, Italy and others. shows that “MicroRNA therapy stimulates uncontrolled cardiac repair after myocardial infarction in pigs.” This study was published, in the 8 May 2019 issue of the prestigious journal Nature (Impact factor: 41.577), by Prof Giacca M, Gabisonia and others.
An earlier study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published, in the 7 March 2013 issue of of the journal Nature, by Prof Dimmler, Boon, and others.
What we say:
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Intracardiac/epicardial injection of Carvedilol protects against & promotes repair & functional recovery after Myocardial Infarction: Carvedilol (brand name: Coreg) , used to treat high blood pressure, congestive heart failure, left ventricular dysfunction and others, inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of its target gene
From Significance of the study to Public Health relevance:
Given that: (1) cardiovascular disease is the leading cause of death worldwide; (2) the raise of death rate, due to cardiovascular disease, has increased from 123 lakhs in 1990 to 173 lakhs in 2013; (3) 85% of people over 80 years are susceptible to cardiovascular diseases;(4) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; (3) the death due to cardiovascular disease is higher in low-to-middle income countries compared to developed countries; (4) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars; (5) an alarming number of people, such as 230 lakhs people, will die from cardiovascular diseases each year by 2030, there is an urgent need to find: (i) a way to induce regeneration of cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs; and (iv) a side-effect-free Natural product-based drug.
From Research Findings to Therapeutic Opportunity:
This study provides, for the first time, mechanistic insight into how vasodilatory beta-blocker Carvedilol protects against and promotes functional recovery after myocardial infarction. Though this drug is the 30th most prescribed drug in the US, its mechanistic of action is far from clear, especially as to how it protects against myocardial dysfunction. Intracardiac/epicardial injection of Carvedilol, by increasing the expression of its target genes, it may increase the expression of PNUTS, MiR-199-a-3p and others (fig.1) . Thereby, it may: (1) inhibit DNA damage responses, (2) increase telomerase expression, (3) inhibit telomere shortening; (4) promote cardiomyocyte repair/survival/dedifferentiation/regeneration; (5) decelerate aging; and (6) extend lifespan (fig 1).
Thus, by injecting carvedilol into the myocardium of aged cardiac patients or by regularly taking carvedilol, one may not only improve cardiac function after myocardial infarction, but also prevent ageing-associated (or, stress-associated) decline in cardiac function. Together, this study suggests that Carvedilol or its analogs, either alone or in combination with other cardio-protective agents, may be used to protect against myocardial infarction or improve cardiac function after myocardial infarction (fig. 2).
Details of the research findings:
Idea Proposed/Formulated (with experimental evidence) by:
Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed mechanistic information: How does carvedilol increase the expression of PNUTS/Telomerase/MiR-199a-3p?
# Research cooperation
For purchase and payment details, you may reach us at email@example.com
Citation: Boominathan, L., Intracardiac/epicardial injection of Carvedilol protects against & promotes repair & functional recovery after Myocardial Infarction: Carvedilol (brand name: Coreg) , used to treat high blood pressure, congestive heart failure, left ventricular dysfunction and others, inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of its target gene, 15/May/2019, 11.47 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at firstname.lastname@example.org